2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerance
2019
Face transplantation
Sinha I, Vyas R, Pomahac B. Face transplantation. 2019, 379-382. DOI: 10.1093/med/9780199699537.003.0045.Peer-Reviewed Original ResearchReturn of sensationSevere traumatic injuryComposite tissue allotransplantationComposite tissue transplantationFacial composite tissue allotransplantationTransplanted allograftPost transplantationLifelong immunosuppressionMotor functionTraumatic injuryTissue allotransplantationPsychiatric issuesPatientsTissue transplantationInfection riskTransplantationFace transplantationFacial formImmunosuppressionAllograftsAllotransplantationInjuryPossible rejectionMonths
2014
Fortschritte in der Gesichtstransplantation
Kueckelhaus M, Lehnhardt M, Fischer S, Eriksson E, Pomahac B, Hirsch T. Fortschritte in der Gesichtstransplantation. Handchirurgie · Mikrochirurgie · Plastische Chirurgie 2014, 46: 206-213. PMID: 25162238, DOI: 10.1055/s-0034-1385850.Peer-Reviewed Original ResearchConceptsVascularised composite allotransplantationFace transplantationLife-threatening side effectsSolid organ transplantationDifferent transplant centersImmunosuppressive regimensMaintenance immunosuppressionVCA proceduresImmunosuppressive strategiesTransplant centersPatients' qualityLifelong immunosuppressionOrgan preservationSurgical techniqueOrgan transplantationComposite allograftsComposite allotransplantationSide effectsTransplantationFunctional reintegrationImmunosuppressionAnatomic structuresImmunogenic partFirst caseDifferent protocols
2013
Vascularized composite tissue allotransplantation – state of the art
Diaz‐Siso J, Bueno E, Sisk G, Marty F, Pomahac B, Tullius S. Vascularized composite tissue allotransplantation – state of the art. Clinical Transplantation 2013, 27: 330-337. PMID: 23581799, PMCID: PMC3724233, DOI: 10.1111/ctr.12117.Peer-Reviewed Original ResearchConceptsImmunosuppression-related side effectsVascularized composite tissue allotransplantationLong-term graft lossEarly post-operative periodChronic graft deteriorationPost-operative periodLong-term outcomesViable treatment optionConventional reconstructive techniquesComposite tissue allotransplantationAcute rejectionGraft lossGraft deteriorationTolerance inductionTreatment optionsLifelong immunosuppressionLower extremitiesImmune responseAnatomic locationReconstructive techniquesAbdominal wallSide effectsTissue allotransplantationFunctional restorationCellular therapy
2011
Evolution of indications for facial transplantation
Pomahac B, Diaz-Siso J, Bueno E. Evolution of indications for facial transplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2011, 64: 1410-1416. PMID: 21843979, DOI: 10.1016/j.bjps.2011.06.024.Peer-Reviewed Original ResearchConceptsLong-term outcomesFace transplantationUnknown long-term outcomesAbsolute exclusion criteriaInstitutional review board approvalExpansion of indicationsReview board approvalPartial face transplantationFacial transplantationFacial defectsEvolution of indicationsSevere facial defectsFacial functionLifelong immunosuppressionCurrent indicationsExclusion criteriaBoard approvalTransplantationSafe reductionSensory functionPatientsPotential patientsTransplantation studiesImmunosuppressionIndications